Grafting Aptamers onto Gold Nanostars Increases in Vitro Efficacy in a Wide Range of Cancer Cell Types

被引:72
作者
Dam, Duncan Hieu M. [1 ]
Culver, Kayla S. B. [2 ]
Odom, Teri W. [1 ,2 ]
机构
[1] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA
[2] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA
基金
美国国家卫生研究院;
关键词
aptamers; gold nanostars; nucleolin; anticancer agents; BCL-2; MESSENGER-RNA; BREAST-CANCER; TUMOR HETEROGENEITY; NUCLEOLIN; THERAPY; AS1411; IDENTIFICATION; STABILIZATION; NANOPARTICLES; THERAPEUTICS;
D O I
10.1021/mp4005657
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We report the design of a nanoconstruct that can function as a cell-type independent agent by targeting the ubiquitous protein nucleolin. Gold nanostars (AuNS) loaded with high densities of nucleolin-specific DNA aptamer AS1411 (Apt-AuNS) produced anticancer effects in a panel of 12 cancer lines containing four representative subcategories. We found that the nanoconstructs could be internalized by cancer cells and trafficked to perinuclear regions. Apt-AuNS resulted in downregulation of antiapoptotic Bcl-2 mRNA expression by ca. 200% compared to cells without the nanoconstructs. The caspase 3/7 activity (apoptosis) and cell death in cancer cells treated with Apt-AuNS increased by 1.5 times and by ca. 17%, respectively, compared to cells treated with free AS1411 at over 10 times the concentration. Moreover, light-triggered release of aptamer from the AuNS further enhanced the in vitro efficacy of the nanoconstructs in the cancer line panel with a 2-fold increase in caspase activity and a 40% decrease in cell viability compared to treatment with Apt-AuNS only. In contrast, treatments of the nanoconstructs with or without light-triggered release on a panel of normal cell lines had no adverse effects.
引用
收藏
页码:580 / 587
页数:8
相关论文
共 37 条
  • [1] Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
    Bates, Paula J.
    Laber, Damian A.
    Miller, Donald M.
    Thomas, Shelia D.
    Trent, John O.
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2009, 86 (03) : 151 - 164
  • [2] MAJOR NUCLEOLAR PROTEINS SHUTTLE BETWEEN NUCLEUS AND CYTOPLASM
    BORER, RA
    LEHNER, CF
    EPPENBERGER, HM
    NIGG, EA
    [J]. CELL, 1989, 56 (03) : 379 - 390
  • [3] New approaches for cell-specific targeting: identification of cell-selective peptides from combinatorial libraries
    Brown, KC
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2000, 4 (01) : 16 - 21
  • [4] An improved synthesis of high-aspect-ratio gold nanorods
    Busbee, BD
    Obare, SO
    Murphy, CJ
    [J]. ADVANCED MATERIALS, 2003, 15 (05) : 414 - +
  • [5] Direct Observation of Nanoparticle-Cancer Cell Nucleus Interactions
    Dam, Duncan Hieu M.
    Lee, Jung Heon
    Sisco, Patrick N.
    Co, Dick T.
    Zhang, Ming
    Wasielewski, Michael R.
    Odom, Teri W.
    [J]. ACS NANO, 2012, 6 (04) : 3318 - 3326
  • [6] Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications
    Dapic, V
    Bates, PJ
    Trent, JO
    Rodger, A
    Thomas, SD
    Miller, DM
    [J]. BIOCHEMISTRY, 2002, 41 (11) : 3676 - 3685
  • [7] TUMOR HETEROGENEITY AND DRUG-RESISTANCE
    DEXTER, DL
    LEITH, JT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (02) : 244 - 257
  • [8] VEGF-targeted therapy: mechanisms of anti-tumour activity
    Ellis, Lee M.
    Hicklin, Daniel J.
    [J]. NATURE REVIEWS CANCER, 2008, 8 (08) : 579 - 591
  • [9] Ginisty H, 1999, J CELL SCI, V112, P761
  • [10] AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin
    Girvan, Allicia C.
    Teng, Yun
    Casson, Lavona K.
    Thomas, Shelia D.
    Juliger, Simone
    Ball, Mark W.
    Klein, Jon B.
    Pierce, William M., Jr.
    Barve, Shirish S.
    Bates, Paula J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (07) : 1790 - 1799